GlassScriptPhysician profile
Lauren Cronenberg Self
NPI 1801815774
$4,476.44
in general payments reported to CMS, 2019-2025
39 companies · $687 in 2025
The $687 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $328 · 2021: $928 · 2022: $876 · 2023: $552 · 2024: $588 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.25 | 2019-2023 | Lo Loestrin Fe, Orilissa, Qulipta |
| Sumitomo Pharma America, INC. | $569.79 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $300.72 | 2022-2025 | |
| Novo Nordisk INC | $278.51 | 2019-2022 | |
| Pfizer INC. | $260.95 | 2019-2025 | |
| Therapeuticsmd, INC. | $246.13 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.18 | 2019-2025 | |
| Astellas Pharma US INC | $195.24 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $186.64 | 2019-2022 | |
| Myovant Sciences INC. | $176.87 | 2021-2022 | |
| Organon LLC | $170.32 | 2022-2025 | Nexplanon, Jada System |
| Shield Therapeutics INC | $148.71 | 2023-2025 | Accrufer |
| Sage Therapeutics, LLC | $129.18 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $121.09 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $97.97 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Self listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.